Background: Alopecia areata (AA) is an autoimmune disorder characterized by nonscarring alopecia affecting scalp and body hair. Treatment of AA in pediatric age group is challenging because of unpredictable course, uncertain natural history, potential side effects of medicines, and psychological morbidity. Moreover, no clear guidelines for treatment of pediatric AA are available.
INTRODUCTION
A lopecia areata (AA) is an idiopathic nonscarring disorder with multifactorial autoimmune pathogenesis affecting hair resulting in patches of noncicatricial baldness on scalp, face, and other hair-bearing skin of the body. [1, 2] This lymphocyte mediated inflammatory process not only targets hair follicles, but also affects the quality of life greatly. The disease can present with one or more well-circumscribed focal bald patch enlarging centrifugally. [1] Alopecia totalis (AT) and alopecia universalis (AU) are other extensive but less common form which affect entire scalp hair and all body hair, respectively. [1, 3] Sometimes AA may present in a unique pattern of hair loss localized to the sides and lower back of the scalp known as ophiasis (OP).
Pediatric AA is frequently encountered in our daily practice. Up to one-third of newly diagnosed cases are aged 20 years or less. [4, 5] AA may be associated with other autoimmune diseases, such as thyroid disease, celiac disease, vitiligo, irritable bowel syndrome, SLE, rheumatoid arthritis, diabetes mellitus, and atopy. [3, 6] Nail changes, including twenty nail dystrophy syndrome and a positive family history, have also been associated with pediatric AA. [2] Factors such as unpredictable course, uncertain natural history, frequent relapses, risk of progression to AT or AU, significant psychosocial morbidity in children, and possible adverse effects of medicines make the management of pediatric AA more challenging. [2, 7] Recalcitrant and extensive AA requires even more comprehensive approach. [8] In this study, we used a combination of daily oral prednisolone in tapering dose, topical mometasone furoate, and topical minoxidil 2% lotion in extensive and recalcitrant AA. This combination was chosen because systemic prednisolone checks the progression of disease activity, while topical minoxidil and mometasone furoate supplement systemic steroids initially and facilitate early withdrawal of systemic steroids by maintaining hair growth and reducing relapse.
Objective
The objective of this study is to assess efficacy and safety of a combination treatment of extensive and recalcitrant AA with oral and topical steroid along with topical minoxidil.
MATERIALS AND METHODS

Subjects
Sixteen children, nine females, and seven males, aged 6-15 years with extensive and recalcitrant AA attending the hair clinic from January 2009 to December 2011 were recruited for this study. We labeled AA as extensive if patient had more than 50% scalp involvement or there is a presence of OP, AT, or AU at presentation [8] and recalcitrant if patient had received various modalities of treatment in the form of oral steroid, pulse therapy, levamisole, tacrolimus, minoxidil, intralesional corticosteroid therapy, or herbal products with poor/partial response or relapse on discontinuing therapy. A wash-out period of 3 months was allowed before starting these patients on the new study regime. Any patient with a history of uncontrolled bacterial, viral, fungal, mycobacterial, or opportunistic infection (e.g., systemic fungal infections or parasites) was excluded from the study. Patients with significant pulmonary or cardiovascular disease, liver disease, or abnormal hepatic function were also not permitted to enter the study.
The nature of the study and possible adverse effects of the therapy was explained and written consent including the consent of medical photography was taken from parents of all patients. All patients were then treated with the study regimen of combination therapy.
Treatment Procedure
All patients were started with once daily oral prednisolone (1 mg/kg) along with topical mometasone and 2% topical minoxidil solution. Oral prednisolone was reduced to 30% of the initial dose at completion of 2 weeks, then tapered down slowly to stop completely in 12 weeks. One milliliter of topical minoxidil was applied to the affected scalp 12 hourly. Topical mometasone solution was applied twice daily 2 h after the last application of minoxidil. The dose of topical mometasone solution was reduced according to the response of the patient and completely withdrawn at the end of 24 weeks. Topical minoxidil was continued for further 12 months as maintenance therapy which included tapering the number of applications of topical minoxidil from twice daily to once a day then alternate days. First 12 weeks were considered as phase I when all the three drugs were continued. phase II was the next 12 weeks when patients were on topicals only without oral steroid and last 12 months of maintenance with topical minoxidil was labeled as Phase III.
Assessment
All patients underwent a comprehensive workup at baseline, 1 st month and at the end of the 3 rd month which included weight and growth assessment, complete physical examination, and investigations such as complete hemogram, blood sugar levels, liver and renal function tests, chest X-ray, and ophthalmological examination. The extent of AA was noted. After completion of the 3 rd month, only hair growth was assessed at monthly interval. The response was classified as cosmetically acceptable, partial response, and no response. "Cosmetically acceptable" has been defined as amount of terminal hair growth sufficient to cover the scalp and conceal the areas of residual loss or patient no longer needing a wig or cap to conceal hair loss, [9] but when the amount of dense patches of terminal hair are not sufficient to conceal the area of residual loss or does not obviate the need of a wig or cap, is taken as partial response. Nonresponder or failure is defined as no growth or vellus hair only, even after 24 weeks of therapy. [8] 
RESULTS
Total 16 patients from age 6 to 15 years were recruited in the study, including nine girls and seven boys (M:F ratio was 1:1.28) average age was 10.81 years (standard deviation = 2.73). The average duration of disease at the time of presentation was 12 months for boys and 9.66 months for girls, ranged from 3 months to 30 months. Among all recruited patients, 1 had AU, 3 had AT, 1 had OP, and 11 had extensive AA (more than 50% scalp involvement). Details of all patients are given in Table 1 . Out of 11 patients with extensive AA, 3 attained good cosmetic response at 12-14 weeks only [ Figure 1 ]. Cosmetically acceptable response was attained in 56% of the patients [ Figures 2 and 3 ], whereas 31% patients showed a partial response. Poor or no response was seen in the patient with AU and in one of the three patients of AT. All responders were maintained on minoxidil solution 2% and followed up for Relapse was seen in one patient with AT and three patients of extensive AA in Phase II. All were mild to moderate and treated with addition of topical steroids. Topical steroids were withdrawn gradually without any further relapse. Same three responders with severe AA relapsed in Phase III also. Topical minoxidil solution 2% was also withdrawn gradually over the 12 month follow-up period without any new relapse except those three patients. Details of response and relapse are shown in Table 2 .
Most commonly seen side effects were weight gain and acneiform eruptions in 50% of the patients and folliculitis on the scalp in 25%. Side effects were mild which required no changes in the doses and were controlled with topical therapy and planned tapering of the doses of oral steroids. Two patients complained of scalp pruritus in first 2 weeks of therapy, probably caused by minoxidil solution but subsided spontaneously.
Two of the sixteen patients had an abnormal level of thyroid stimulating hormone and one of them also had elevated levels of thyroid autoantibodies. Personal history suggestive of atopy was found in one patient. The family history of AA was found in three patients.
DISCUSSION
AA is a common human disease with a lifetime risk of 1.7% in general population [10] and the lifetime incidence of approximately 2% worldwide. [6] It may be observed at any age and has no clear sex predominance. A study done in North India showed a preponderance in men (M:F = 2:1) [5] but in another clinical study of childhood AA done in Chandigarh, India, the F:M ratio was found to be 1.4:1. [11] The same finding was seen in a studies done in Kuwait and Singapore, where girls outnumbered boys by a 2.5:1 and 1.3:1 ratio, respectively. [12, 13] We also found a slight female preponderance in extensive and recalcitrant AA (F:M = 1.28:1).
There are several topical and systemic modalities for treatment of AA described in literature but there is a paucity of well-designed randomized trials for treatment guideline, especially for childhood AA. Many different regimens of systemic corticosteroids, including single-dose, short-term with high dose, alternate day dosing, or tapering dosing by oral or intravenous (IV) route have been tried with different success rates, but long-term safety data are not well-established. [14] [15] [16] [17] [18] [19] The only placebo-controlled randomized study on oral prednisolone was done by Kar et al. where pulse therapy of 200 mg oral prednisolone over 3 months showed regrowth in 60% of the patients compared with no regrowth in the placebo arm. But relapse was seen in 25% of the responders. [14] In two other studies, 300 mg oral prednisolone once a month showed cosmetically acceptable response in 82% patients over 3-6 months, [15] and in 58% of patients with extensive AA and AT/AU in 4 months period. [16] Regimen using alternate day prednisolone was not found to be substantially effective and beneficial in the natural course of AA in long-term. Moreover, this regimen reported the occurrence of side effects such as striae, acne, obesity, mild hypertension lenticular opacities, and impaired adrenocorticotropic hormone reserve. [17] Large single-dose of prednisolone was also tried and found to be unsatisfactory in a study done by Burton and Shuster where they used prednisolone as a single 2 g dose IV or 500 mg orally for 5 days in patients with AT. [18] Pulse IV methylprednisolone has been found to be beneficial in several studies. Friedli et al. showed 50-100% regrowth in 60% patients of multifocal, patchy AA, but this regimen was found ineffective in patients with AT, AU, or OP. [19, 20] In children with extensive patchy AA or AT/AU, high dose pulse methylprednisolone was shown to have a poor long-term outcome in one study whereas few other studies found pulsed oral corticosteroids effective. [21] [22] [23] In a comparative study between dexamethasone 0.5 mg/day for 6 months, intramuscular triamcinolone acetonide 40 mg once a month for 6 months followed by 40 mg once every 1.5 months for 1 year and pulse therapy with oral prednisolone at 80 mg for three consecutive days once every 3 months, best response was found with intramuscular triamcinolone acetonide in patients with multifocal AA and relapse rates were found to be the lowest in the patient who received pulse therapy with oral prednisolone. [24] In few other studies, treatment with oral prednisolone in tapering dose was combined with or followed by topical minoxidil daily. The tapering dose of prednisolone offered potential for regrowth with predictable and transient side effects and topical minoxidil helped to limit poststeroid hair loss. [25, 26] The mechanism by which topical minoxidil stimulates hair regrowth is unknown, but a direct follicular effect is thought to be present. [8] When used as monotherapy, topical minoxidil is not very effective for those with 100% scalp hair loss, but it is an effective, easy, and safe treatment for those with AA affecting 25-99% of the scalp. [27] Therefore, it was hypothesized that combining minoxidil with oral steroid has synergistic action and is more effective than monotherapy of either.
In 1978, Unger and Schemmer suggested low-dose oral prednisone combined with intralesional and topical corticosteroids in patients with AT and AU and found virtually all scalp hair regrowth in about 46% patients and all patients were able to discontinue oral corticosteroids without recurrence of AT or AU. [28] In view of above studies, we proposed a combined therapy consisting of oral and topical steroids and topical minoxidil, with gradual tapering down of oral steroid first followed by topical steroid and lastly minoxidil solution as it is the least harmful drug.
In our study, the cosmetic response was seen in 56% and partial response in 31% of the total patients. All patients with extensive AA (excluding AT and AU) responded to our regimen, 66.6% showed cosmetic response whereas only partial response was achieved in 33.3% of them. About 25% responders relapsed in Phase I and II and could not show satisfactory response after stopping the oral medication. Patient with OP showed good response without any relapse. Among the patients with AT, 66% patients responded with the regimen but 33% relapsed in Phase II. Relapse was managed effectively without any further relapse in the maintenance phase.
Patient with AU failed to respond our regimen. In general, success rates are found to be much better in multifocal extensive AA with systemic corticosteroids compared with AT and AU. [15, 18, 19] We also found the same in our study. The drawbacks of systemic corticosteroids are their side effect profile and the fact that they do not alter the long-term prognosis. Side effects of long-term systemic steroids include growth retardation, hyperglycemia, osteoporosis, cataracts, immunosuppression, obesity, dysmenorrhea, acne, weight gain, mood changes/emotional lability, and Cushing's syndrome, [14, 24, 29] but tapering course of short-term systemic corticosteroid does not produce any major adverse effects even in children. In our study, side effects were predictable, mild and reversible, in the form of local scalp irritation, weight gain, acneiform eruptions, and folliculitis.
A small number of patients was the major limitation in our study, as the results of this study may not represent the actual effect of our regimen in all pediatric patients of AA in general population. Inability to perform long-term follow-up was another major limitation as long-term prognosis could not be assessed. Because of the high rate of spontaneous hair regrowth, which is almost 50% with limited disease, [2] studies with a large number of patients are required either after exclusion of spontaneous remission by treating each patient on one-half of the scalp only or by conducting double-blind, placebo-controlled studies.
CONCLUSION
AA can persist for many years or even for life. Therefore, therapeutic approaches showing severe side effects are inappropriate for treatment in the long run. The actual challenge is to choose a treatment modality suitable for long-term treatment with least side effects. Although there are no well-designed large trials examining the effects of daily systemic corticosteroids in childhood AA, it has been shown to be able to induce regrowth in adult AA. But serious adverse effects of long-term corticosteroid therapy limit its use in children. Hence, it should be reserved for patients with rapid onset or rapidly progressive, extensive and active AA, and oral prednisolone should be slowly tapered over 2 months, not exceeding 3 months. [2] Still the maintenance of hair growth is difficult and unpredictable. On the other hand, alternate day steroids or pulsed dosing may be inadequate. However, using topical corticosteroids and minoxidil along with oral prednisolone allows for more rapid lowering of oral doses with maintaining the cosmetic response and minimizing the side effects. Therefore, a trial course of oral and topical corticosteroid treatment with topical minoxidil would seem to be a reasonable approach for extensive, treatment-resistant, and nearly hopeless but highly motivated pediatric patients of AA.
